TherapeuticsMD, Inc. (TXMD) Shares Bought by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. grew its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 293.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 112,900 shares of the company’s stock after acquiring an additional 84,170 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.06% of TherapeuticsMD worth $595,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of TherapeuticsMD by 12.7% in the second quarter. Bank of New York Mellon Corp now owns 22,892,018 shares of the company’s stock valued at $120,642,000 after buying an additional 2,574,120 shares during the period. JPMorgan Chase & Co. increased its stake in shares of TherapeuticsMD by 14.3% in the second quarter. JPMorgan Chase & Co. now owns 15,687,509 shares of the company’s stock valued at $82,674,000 after buying an additional 1,961,656 shares during the period. Stifel Financial Corp increased its stake in shares of TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after buying an additional 1,622,668 shares during the period. Voya Investment Management LLC increased its stake in shares of TherapeuticsMD by 33.4% in the second quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock valued at $15,595,000 after buying an additional 741,588 shares during the period. Finally, State Street Corp increased its stake in shares of TherapeuticsMD by 14.9% in the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock valued at $23,647,000 after buying an additional 583,094 shares during the period. 71.54% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Tommy G. Thompson bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was bought at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 23.92% of the company’s stock.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million during the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative return on equity of 74.25% and a negative net margin of 485.71%. TherapeuticsMD’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.11) EPS.

WARNING: “TherapeuticsMD, Inc. (TXMD) Shares Bought by Raymond James Financial Services Advisors Inc.” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/02/therapeuticsmd-inc-txmd-shares-bought-by-raymond-james-financial-services-advisors-inc.html.

Several research analysts have recently issued reports on TXMD shares. Oppenheimer Holdings, Inc. raised TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research note on Friday, July 21st. CIBC raised TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, September 8th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $14.88.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

What are top analysts saying about TherapeuticsMD Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit